Salient launches new device to improve patient outcomes in spine surgery

139

The company’s Aquamantys Epidural Vein Sealer uses advanced energy to reduce bleeding in hard-to-reach areas.

As part of its ongoing effort to improve patient outcomes for spinal procedures, Salient Surgical Technologies recently unveiled the Aquamantys Epidural Vein Sealer (EVS) bipolar device.


The epidural vein sealer is designed to address the challenging anatomy in minimally invasive spine surgery and is the latest product introduction on Salient’s proprietary Aquamantys platform. The EVS employs Transcollation advanced energy technology to significantly reduce bleeding in hard-to-reach areas. Reducing blood loss improves visualisation for the surgeon, can result in improved clinical outcomes for the patient and may result in lower costs to the hospital.


Transcollation technology is a calibrated fusion of radiofrequency energy and saline that gently seals bleeding tissues, vessels and bone at the surgical site. A remarkable feature in the EVS is the ability to deliver Transcollation technology through miniaturised electrodes, which provide direct and precise compression of epidural veins around critical structures. The EVS is used with the same Aquamantys System Generator as Salient’s standard 2.3 and 6.0 Bipolar Sealer devices.


“The EVS represents the latest in a series of innovations designed to improve patient outcomes and reduce hospital costs that we have planned for 2009,” said Joe Army, CEO of Salient Surgical Technologies.


Salient’s Aquamantys System uses Transcollation technology to help surgeons improve patient outcomes for orthopedic reconstruction, spinal fusion and solid organ resection procedures. To date, Transcollation technology has been used in over 250,000 surgical procedures.

 

 

(Visited 33 times, 1 visits today)